Open
Do sulfonylureas & glinides improve inflammation & biomarkers more than other treatments?
Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 1
- Inconclusive
- 2
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 34
- With posted results
- 7
- Published papers
- 2
Of 6 decided analyses: 0 favor sulfonylureas & glinides, 4 find no difference, 2 favor the comparator.
Papers
- Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.Trial report · 2018
- Leptin and body fat in type 2 diabetes and monodrug therapy.Trial report · 2003
Trials
- Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic DyslipidemiaNCT00770653 · 3 posted results
- The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride ArmNCT00620282 · 3 posted results
- Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With MetforminNCT02564926 · 1 posted result
- Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?NCT02879409
- Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 DiabetesNCT04183868
- The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery DiseasesNCT03693560
- A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and GlycaemiaNCT00379769 · 3 posted results
- A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes MellitusNCT00279045